Comparison Between Urothelial and Non-Urothelial Urethral Cancer
Status PubMed-not-MEDLINE Language English Country Switzerland Media electronic-ecollection
Document type Journal Article
PubMed
33585257
PubMed Central
PMC7880052
DOI
10.3389/fonc.2020.629692
Knihovny.cz E-resources
- Keywords
- adenocarcinoma, chemotherapy, metastatic urethral cancer, mortality, non-urothelial, squamous cell carcinoma, urethral cancer, variant histology,
- Publication type
- Journal Article MeSH
BACKGROUND: To test the effect of variant histology relative to urothelial histology on stage at presentation, cancer specific mortality (CSM), and overall mortality (OM) after chemotherapy use, in urethral cancer. MATERIALS AND METHODS: Within the Surveillance, Epidemiology and End Results (2004-2016) database, we identified 1,907 primary variant histology urethral cancer patients. Kaplan-Meier plots, Cox regression analyses, cumulative incidence-plots, multivariable competing-risks regression models and propensity score matching for patient and tumor characteristics were used. RESULTS: Of 1,907 eligible urethral cancer patients, urothelial histology affected 1,009 (52.9%) vs. squamous cell carcinoma (SCC) 455 (23.6%) vs. adenocarcinoma 278 (14.6%) vs. other histology 165 (8.7%) patients. Urothelial histological patients exhibited lower stages at presentation than SCC, adenocarcinoma or other histology patients. In urothelial histology patients, five-year CSM was 23.5% vs. 34.4% in SCC [Hazard Ratio (HR) 1.57] vs. 40.7% in adenocarcinoma (HR 1.69) vs. 43.4% in other histology (HR 1.99, p < 0.001). After matching in multivariate competing-risks regression models, variant histology exhibited 1.35-fold higher CSM than urothelial. Finally, in metastatic urethral cancer, lower OM was recorded after chemotherapy in general, including metastatic adenocarcinoma and other variant histology subtypes, except metastatic SCC. CONCLUSION: Adenocarcinoma, SCC and other histology subtypes affect fewer patients than urothelial histology. Presence of variant histology results in higher CSM. Finally, chemotherapy for metastatic urethral cancer improves survival in adenocarcinoma and other variant histology subtypes, but not in SCC.
Department of Urology 2nd Faculty of Medicine Charles University Prague Czechia
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology University of Texas Southwestern Dallas TX United States
Departments of Urology Weill Cornell Medical College New York NY United States
See more in PubMed
Swartz MA, Porter MP, Lin DW, Weiss NS. Incidence of primary urethral carcinoma in the United States. Urology (2006) 68(6):1164–8. 10.1016/j.urology.2006.08.1057 PubMed DOI
Gakis G, Witjes JA, Compérat E, Cowan NC, De Santis M, Lebret T, et al. EAU guidelines on primary urethral carcinoma. Eur Urol (2013) 64(5):823–30. 10.1016/j.eururo.2013.03.044 PubMed DOI
Aleksic I, Rais-Bahrami S, Daugherty M, Agarwal PK, Vourganti S, Bratslavsky G. Primary urethral carcinoma: A Surveillance, Epidemiology, and End Results data analysis identifying predictors of cancer-specific survival. Urol Ann (2018) 10(2):170–4. 10.4103/UA.UA_136_17 PubMed DOI PMC
Champ CE, Hegarty SE, Shen X, Mishra MV, Dicker AP, Trabulsi EJ, et al. Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology (2012) 80(2):374–81. 10.1016/j.urology.2012.02.058 PubMed DOI
Rabbani F. Prognostic factors in male urethral cancer. Cancer (2011) 117(11):2426–34. 10.1002/cncr.25787 PubMed DOI
Derksen JW, Visser O, de la Rivière GB, Meuleman EJ, Heldeweg EA, Lagerveld BW. Primary urethral carcinoma in females: an epidemiologic study on demographical factors, histological types, tumour stage and survival. World J Urol (2013) 31(1):147–53. 10.1007/s00345-012-0882-5 PubMed DOI
Mano R, Vertosick EA, Sarcona J, Sjoberg DD, Benfante NE, Donahue TF, et al. Primary urethral cancer: treatment patterns and associated outcomes. BJU Int (2020) 126(3):359–66. 10.1111/bju.15095 PubMed DOI PMC
Gakis G, Morgan TM, Daneshmand S, Keegan KA, Todenhöfer T, Mischinger J, et al. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. Ann Oncol (2015) 26(8):1754–9. 10.1093/annonc/mdv230 PubMed DOI
Kent M, Zinman L, Girshovich L, Sands J, Vanni A. Combined chemoradiation as primary treatment for invasive male urethral cancer. J Urol (2015) 193(2):532–7. 10.1016/j.juro.2014.07.105 PubMed DOI
About the SEER Program SEER. National Cancer Institute; (2020). Available at: https://seer.cancer.gov/about/overview.html.
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol (2016) 70(1):106–19. 10.1016/j.eururo.2016.02.028 PubMed DOI
Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. UICC International Union Against Cancer. Wiley/Blackwell; (2017).
Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer (2013) 49(8):1889–97. 10.1016/j.ejca.2013.02.001 PubMed DOI
Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Mistretta FA, et al. The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. Am J Clin Oncol (2020) 43(8):567–74. 10.1097/COC.0000000000000704 PubMed DOI
Deuker M, Franziska Stolzenbach L, Rosiello G, Luzzago S, Martin T, Tian Z, et al. Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. Eur J Surg Oncol (2020) S0748-7983(20)30459-5. 10.1016/j.ejso.2020.05.006 PubMed DOI
Incidence rates and contemporary trends in primary urethral cancer
